S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   277.71 (+2.23%)
AAPL   116.00 (+4.32%)
MSFT   204.13 (+0.72%)
FB   278.36 (+3.99%)
GOOGL   1,693.00 (+12.06%)
AMZN   3,195.52 (+1.04%)
TSLA   410.70 (+1.15%)
NVDA   518.03 (+2.56%)
BABA   313.00 (+1.64%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.12 (+0.24%)
AMD   77.95 (+2.03%)
T   26.74 (+0.91%)
F   7.91 (+2.73%)
ACB   4.09 (+6.79%)
GILD   58.26 (-0.78%)
NFLX   502.75 (+3.40%)
NIO   31.56 (+14.72%)
BA   148.26 (+0.08%)
DIS   121.70 (+2.73%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   277.71 (+2.23%)
AAPL   116.00 (+4.32%)
MSFT   204.13 (+0.72%)
FB   278.36 (+3.99%)
GOOGL   1,693.00 (+12.06%)
AMZN   3,195.52 (+1.04%)
TSLA   410.70 (+1.15%)
NVDA   518.03 (+2.56%)
BABA   313.00 (+1.64%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.12 (+0.24%)
AMD   77.95 (+2.03%)
T   26.74 (+0.91%)
F   7.91 (+2.73%)
ACB   4.09 (+6.79%)
GILD   58.26 (-0.78%)
NFLX   502.75 (+3.40%)
NIO   31.56 (+14.72%)
BA   148.26 (+0.08%)
DIS   121.70 (+2.73%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   277.71 (+2.23%)
AAPL   116.00 (+4.32%)
MSFT   204.13 (+0.72%)
FB   278.36 (+3.99%)
GOOGL   1,693.00 (+12.06%)
AMZN   3,195.52 (+1.04%)
TSLA   410.70 (+1.15%)
NVDA   518.03 (+2.56%)
BABA   313.00 (+1.64%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.12 (+0.24%)
AMD   77.95 (+2.03%)
T   26.74 (+0.91%)
F   7.91 (+2.73%)
ACB   4.09 (+6.79%)
GILD   58.26 (-0.78%)
NFLX   502.75 (+3.40%)
NIO   31.56 (+14.72%)
BA   148.26 (+0.08%)
DIS   121.70 (+2.73%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   277.71 (+2.23%)
AAPL   116.00 (+4.32%)
MSFT   204.13 (+0.72%)
FB   278.36 (+3.99%)
GOOGL   1,693.00 (+12.06%)
AMZN   3,195.52 (+1.04%)
TSLA   410.70 (+1.15%)
NVDA   518.03 (+2.56%)
BABA   313.00 (+1.64%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.12 (+0.24%)
AMD   77.95 (+2.03%)
T   26.74 (+0.91%)
F   7.91 (+2.73%)
ACB   4.09 (+6.79%)
GILD   58.26 (-0.78%)
NFLX   502.75 (+3.40%)
NIO   31.56 (+14.72%)
BA   148.26 (+0.08%)
DIS   121.70 (+2.73%)
Log in
NASDAQ:VRAY

ViewRay Stock Forecast, Price & News

$3.02
+0.05 (+1.68 %)
(As of 10/29/2020 03:59 PM ET)
Add
Compare
Today's Range
$2.92
Now: $3.02▼
$3.09
50-Day Range
$2.80
MA: $3.14▼
$3.50
52-Week Range
$1.11
Now: $3.02▼
$4.88
Volume35,261 shs
Average Volume1.73 million shs
Market Capitalization$446.79 million
P/E RatioN/A
Dividend YieldN/A
Beta0.64
ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
Read More
ViewRay logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRAY
Previous Symbol
CUSIPN/A
CIK1597313
Webwww.viewray.com
Phone440-703-3210
Employees309

Debt

Debt-to-Equity Ratio0.26
Current Ratio3.90
Quick Ratio3.19

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$87.78 million
Price / Sales5.09
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.47 per share
Price / Book2.05

Profitability

EPS (Most Recent Fiscal Year)($1.18)
Net Income$-120,200,000.00
Net Margins-166.74%
Return on Equity-63.41%
Return on Assets-36.34%

Miscellaneous

Outstanding Shares147,945,000
Market Cap$446.79 million
Next Earnings Date11/5/2020 (Confirmed)
OptionableOptionable
$3.02
+0.05 (+1.68 %)
(As of 10/29/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ViewRay (NASDAQ:VRAY) Frequently Asked Questions

How has ViewRay's stock been impacted by COVID-19 (Coronavirus)?

ViewRay's stock was trading at $1.69 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRAY shares have increased by 81.7% and is now trading at $3.07.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of ViewRay?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for ViewRay.

When is ViewRay's next earnings date?

ViewRay is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for ViewRay.

How can I listen to ViewRay's earnings call?

ViewRay will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) posted its quarterly earnings data on Thursday, July, 30th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.02. The business earned $14.22 million during the quarter, compared to the consensus estimate of $5.81 million. ViewRay had a negative net margin of 166.74% and a negative return on equity of 63.41%.
View ViewRay's earnings history.

What price target have analysts set for VRAY?

7 brokers have issued 1-year price objectives for ViewRay's shares. Their forecasts range from $2.00 to $8.00. On average, they expect ViewRay's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 46.6% from the stock's current price.
View analysts' price targets for ViewRay.

Who are some of ViewRay's key competitors?

Some companies that are related to ViewRay include InMode (INMD), BioLife Solutions (BLFS), Natus Medical (NTUS), AxoGen (AXGN), Zynex (ZYXI), Zynex (ZYXI), Semler Scientific (SMLR), TransMedics Group (TMDX), Cutera (CUTR), Stereotaxis (STXS), Stereotaxis (STXS), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Edap Tms (EDAP) and Fonar (FONR).
View all competitors.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

Who are ViewRay's key executives?

ViewRay's management team includes the following people:
  • Mr. Scott William Drake, Pres, CEO & Director (Age 52, Pay $1.23M)
  • Mr. Shahriar Matin, Chief Operating Officer (Age 45, Pay $671.21k)
  • Dr. James F. Dempsey, Chief Scientific Officer (Age 49, Pay $468.31k)
  • Mr. Zachary William Stassen, Chief Financial Officer
  • Ms. Michaella Gallina, VP. Chief of Staff and Head of Investor Relations & Communications

When did ViewRay IPO?

(VRAY) raised $52 million in an IPO on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by many different institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.60%), Hodges Capital Management Inc. (0.06%), Perkins Capital Management Inc. (0.02%) and FNY Investment Advisers LLC (0.01%). Company insiders that own ViewRay stock include James F Dempsey, Scott William Drake and Shahriar Matin.
View institutional ownership trends for ViewRay.

Which institutional investors are selling ViewRay stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A..
View insider buying and selling activity for ViewRay.

Which institutional investors are buying ViewRay stock?

VRAY stock was acquired by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Hodges Capital Management Inc., and FNY Investment Advisers LLC. Company insiders that have bought ViewRay stock in the last two years include Scott William Drake, and Shahriar Matin.
View insider buying and selling activity for ViewRay.

How do I buy shares of ViewRay?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $3.07.

How big of a company is ViewRay?

ViewRay has a market capitalization of $454.19 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. ViewRay employs 309 workers across the globe.

What is ViewRay's official website?

The official website for ViewRay is www.viewray.com.

How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.